184 related articles for article (PubMed ID: 12904142)
21. Safety of statin therapy in patients with preexisting liver disease.
Onofrei MD; Butler KL; Fuke DC; Miller HB
Pharmacotherapy; 2008 Apr; 28(4):522-9. PubMed ID: 18363535
[TBL] [Abstract][Full Text] [Related]
22. Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients.
Descamps O; Tomassini JE; Lin J; Polis AB; Shah A; Brudi P; Hanson ME; Tershakovec AM
Atherosclerosis; 2015 Jun; 240(2):482-9. PubMed ID: 25913444
[TBL] [Abstract][Full Text] [Related]
23. A systematic review and meta-analysis on the therapeutic equivalence of statins.
Weng TC; Yang YH; Lin SJ; Tai SH
J Clin Pharm Ther; 2010 Apr; 35(2):139-51. PubMed ID: 20456733
[TBL] [Abstract][Full Text] [Related]
24. Risk identification and possible countermeasures for muscle adverse effects during statin therapy.
Magni P; Macchi C; Morlotti B; Sirtori CR; Ruscica M
Eur J Intern Med; 2015 Mar; 26(2):82-8. PubMed ID: 25640999
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of intensive statin therapy in the elderly.
Maroo BP; Lavie CJ; Milani RV
Am J Geriatr Cardiol; 2008; 17(2):92-100. PubMed ID: 18326948
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review.
Gudzune KA; Monroe AK; Sharma R; Ranasinghe PD; Chelladurai Y; Robinson KA
Ann Intern Med; 2014 Apr; 160(7):468-76. PubMed ID: 24514899
[TBL] [Abstract][Full Text] [Related]
27. Statin wars: have we been misled about the evidence? A narrative review.
Demasi M
Br J Sports Med; 2018 Jul; 52(14):905-909. PubMed ID: 29353811
[TBL] [Abstract][Full Text] [Related]
28. Drug-drug interactions that interfere with statin metabolism.
Hirota T; Ieiri I
Expert Opin Drug Metab Toxicol; 2015; 11(9):1435-47. PubMed ID: 26058399
[TBL] [Abstract][Full Text] [Related]
29. Statin-associated myopathy.
Thompson PD; Clarkson P; Karas RH
JAMA; 2003 Apr; 289(13):1681-90. PubMed ID: 12672737
[TBL] [Abstract][Full Text] [Related]
30. Statins and cancer: a potential link?
Thompson JS; Sood A; Arora R
Am J Ther; 2010; 17(4):e100-4. PubMed ID: 19451806
[TBL] [Abstract][Full Text] [Related]
31. Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.
Geng Q; Ren J; Chen H; Lee C; Liang W
Curr Med Res Opin; 2013 Mar; 29(3):181-8. PubMed ID: 23323878
[TBL] [Abstract][Full Text] [Related]
32. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
[TBL] [Abstract][Full Text] [Related]
33. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor.
Kajinami K; Takekoshi N; Saito Y
Cardiovasc Drug Rev; 2003; 21(3):199-215. PubMed ID: 12931254
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study--the Ezetrol Add-On Study.
Bissonnette S; Habib R; Sampalis F; Boukas S; Sampalis JS;
Can J Cardiol; 2006 Oct; 22(12):1035-44. PubMed ID: 17036098
[TBL] [Abstract][Full Text] [Related]
35. Nonstatin therapies for management of dyslipidemia: a review.
Sando KR; Knight M
Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
[TBL] [Abstract][Full Text] [Related]
36. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
Chang JT; Staffa JA; Parks M; Green L
Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
[TBL] [Abstract][Full Text] [Related]
37. Lipid lowering inefficacy of high-dose statin therapy due to concurrent use of phenytoin.
Khandwala HM
South Med J; 2006 Dec; 99(12):1385-7. PubMed ID: 17233196
[TBL] [Abstract][Full Text] [Related]
38. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust.
Davidson MH
Drugs; 2001; 61(2):197-206. PubMed ID: 11270938
[TBL] [Abstract][Full Text] [Related]
39. Perspectives of the non-statin hypolipidemic agents.
Rozman D; Monostory K
Pharmacol Ther; 2010 Jul; 127(1):19-40. PubMed ID: 20420853
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
